A Study to Explore Treatment Regimens and Clinical Outcomes of the NSCLC Patients With Different Dirver Genes

Overview

A single-center, non-interventional prospective observational study in the NSCLC patients with different driver genes

Full Title of Study: “A Prospective Observational Study to Explore Treatment Regimens and Clinical Outcomes of the NSCLC Patients With Different Driver Genes”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 1, 2022

Detailed Description

The trial was designed as a single-center non-interventional prospective observational study to explore clinical treatments of the NSCLC patients with different driver genes, the impact factors of patient survivals, and the relevance of gene types, clinical treatments, and distribution of gene types. The follow-up visits, interactions between the investigators and patients, patient questionnaires/quality of life, and other patient information will be uploaded via mobile APP, and webchat every three months.

Interventions

  • Other: Patients with driver genes
    • Patients with driver genes

Arms, Groups and Cohorts

  • NSCLC patients with driver genes
    • NSCLC patients and driver genes

Clinical Trial Outcome Measures

Primary Measures

  • Differences in overall survival rates
    • Time Frame: 2018-2022
    • Differences in overall survival rates of the NSCLC patients with various gene types

Secondary Measures

  • Interaction impact between gene types and treatment modalities or regimens on disease-free survivals
    • Time Frame: 2018-2022
    • Interaction impact between gene types and treatment modalities or regimens on disease-free survivals
  • Statuses of clinical treatment regimens
    • Time Frame: 2018-2022
    • Statuses of clinical treatment regimens of the NSCLC patients
  • Relevance of gene types
    • Time Frame: 2018-2022
    • Relevance of gene types and clinical characteristics of the NSCLC patients
  • Relevance of overall survival rates and gene types
    • Time Frame: 2018-2022
    • Relevance of overall survival rates and gene types of the NSCLC patients
  • Impacts of disease-free survivals on gene types
    • Time Frame: 2018-2022
    • Impacts of disease-free survivals on gene types of the NSCLC patients
  • Impacts of progression-free survivals
    • Time Frame: 2018-2022
    • Impacts of progression-free survivals on gene types of the NSCLC patients
  • Impact factors of overall survivals
    • Time Frame: 2018-2022
    • Impact factors of overall survivals of the NSCLC patients

Participating in This Clinical Trial

Inclusion Criteria

  • The patients with lung cancer who were performed with next-generation sequencing (NGS) technology from 2015 to 2017;
  • The patients who were at least 18 years;
  • The pathologically diagnosed patients with non-small cell lung cancer (NSCLC)

Exclusion Criteria

-None

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • The First Affiliated Hospital of Guangzhou Medical University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Jianxing He, Professor – The First Affiliated Hospital of Guangzhou Medical University
  • Overall Official(s)
    • Wenhua Liang, Ph.D, Principal Investigator, The First Affiliated Hospital of Guangzhou Medical University
  • Overall Contact(s)
    • Jianxing HE, MD, 00862083062114, hejx@vip.163.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.